Reteplase, recombinant

Example Reteplase, recombinant Route IC Pregnancy category C Pharmacokinetic Rapidly cleared from plasma eliminated by the liver and kidney. 

RETEPLASE, RECOMBINANT (Retavase powder for injection, lyophilized 10.4 U (18.1 mg))... 

Alteplase, reteplase Recombinant human protein 2-10 min Active tissue plasminogen activator, (t-PA) converts plasminogen to plasmin intravenous infusion (alteplase) or bolus doses (reteplase) required. Most expensive. Reteplase is somewhat longer-acting than alteplase... 

Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996 4 891-898. 

Reteplase is another recombinant human t-PA from which several amino acid sequences have been deleted. Reteplase is less expensive to produce than t-PA. Because it lacks the major fibrin-binding domain, reteplase is less fibrin-specific than t-PA. Tenecteplase is a mutant form of t-PA that has a longer half-life, and it can be given as an intravenous bolus. Tenecteplase is slightly more fibrin-specific than t-PA. 

Reteplase A fibrinolytic protease a Recombinant genetic Treatment of acute... 

During the time that UK was unavailable, increased experience and familiarity were gained with other agents, such as recombinant tissue plasminogen activator (rt-PA) and reteplase. 

Reteplase is a second-generation recombinant tissue plasminogen activator, which lacks portions of the original alteplase. The chemical structure results in a smaller molecule having less fibrin specificity and a longer half-life than alteplase. Studies from Ouriel et al. and Castaneda et al. demonstrated... 

DNA technology. Reteplase (tV 15 min) is another recombinant human protein. 

Pro-urokinase, alteplase, reteplase, and tenecteplase, which are recombinant products, also appear to be free from allergic reactions. Pro-urokinase and alteplase have short half-lives (3-8 minutes) and require continuous infusion administration, which may in some cases be an advantage as it allows rapid surgical intervention when necessary (53). Reteplase and tenecteplase have substantially longer half-lives, allowing bolus administration. 

Waller, M., Rohnert, U. 1999. Reteplase, a recombinant plasminogen activator. In Biopharmaceuticals, An Industrial Perspective. Walsh,... 

The second, reteplase, a recombinant, is a nonglycosylated deletion mutation of human t-PA containing 355 of 527 amino acids of native t-PA. The drug is indicated for acute myocardial infarction and is given as a 10 U +10 U double bolus. 

---